1Q Pharma Results Preview Biogen Novartis Lilly Amgen GSK AstraZeneca BMS...
Scrip offers some key points to watch for as the biopharmaceutical sales and earnings start to roll in. While the...&160;&160;&160;
View ArticlePursuing Productive Pharma Partnerships In Korea
Multinational and domestic pharma companies operating in South Korea should develop partnerships that build on each others strengths delegates at...&160;&160;&160;
View ArticlePitavastatin an Option for High LDLC With Antiretrovirals for HIV
It seemed more potent against LDL than pravastatin in a small trial; other statins may interfere with some antiHIV drugs. Virologic failure or serious adverse events weren't seen with either statin....
View ArticleNew Findings Highlight the Potential Utility of Pitavastatin for People...
Pitavastatin may have favorable effects to lower cholesterol and dampen inflammation thereby improving cardiovascular disease risk for people living with HIV. Ongoing studies are needed to determine if...
View ArticleSanofi and Regeneron Announce FDA Approval of a New OnceMonthly Dosing Option...
BRIDGEWATER N.J. and TARRYTOWN N.Y. April 25 2017 PRNewswire Sanofi and Regeneron Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration FDA approved the companies' new...
View ArticleRegeneron and Sanofi Announce FDA Approval of a New OnceMonthly Dosing Option...
TARRYTOWN N.Y. and BRIDGEWATER N.J. April 25 2017 PRNewswire Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced that the U.S. Food and Drug Administration FDA approved the companies'...
View ArticleEvolocumab Plus Statins and Progression of Coronary AtherosclerosisReply
In Reply The GLAGOV trial found that administration of evolocumab with statin therapy produced a favorable effect on coronary atherosclerosis characterized by plaque regression compared with statin...
View ArticleEvolocumab Plus Statins and Progression of Coronary Atherosclerosis
To the Editor Dr Nicholls and colleagues found that adding evolocumab vs placebo to statin treatment among patients with coronary disease resulted in a 1 greater decrease in percent atheroma volume PAV...
View ArticleCardiovascular Disorders Drug Development Pipeline Review 2017
LONDON April 25 2017 PRNewswire Summary Cardiovascular disease CVD covers a range of difference diseases and conditions affecting the heart andor blood vessels. The most crucial risk factors for CVD...
View ArticleTeva Announces Launch of Generic Vytorin in the United States
Teva Pharmaceutical Industries Ltd. NYSE and TASETEVA today announced the launch of generic VytorinÂ1 ezetimibe and simvastatin tablets in the U.S. Ezetimibe and simvastatin tablets are a prescription...
View ArticleDaiichi Sankyo Inc Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryDaiichi Sankyo Inc Daiichi Sankyo a subsidiary of Daiichi Sankyo Company Ltd is a pharmaceutical company that discovers and develops medicines for cardiovascular and metabolic disorders. The...
View ArticlePrescribe with Confidence. GenoScribe Live Software by Emgenex is Integrating...
Princeton NJ May 02 2017 PR.com ADEs are the fourth leading cause of death nationwide after heart disease cancer and stroke. Approximately 5 percent of hospital admissions are due to adverse drug...
View ArticleWho Needs a Statin DNA Beats Current Risk Calculators
Dr Mandrola reviews the data on genetic risk scores and sees hope of finally improving our ability to predict CAD risk and which patients will benefit most from statins. theheart.org on Medscape
View ArticleAmgen And Harvard Pilgrim Agree To First Cardiovascular OutcomesBased Refund...
THOUSAND OAKS Calif. May 2 2017 PRNewswire Amgen NASDAQAMGN today announced from the World Medical Innovation Forum focused on cardiovascular disease that Harvard Pilgrim a health services company...
View ArticleHarvard Pilgrim Signs Second Groundbreaking Contract with Amgen For Repatha
HPHC and its members will receive full refund if a cardiac event occurs while on the drug Harvard Pilgrim Health Care has entered into a firstofitskind contract with Amgen for its LDL cholesterol...
View ArticleStatins No increase in musclerelated side effects in patients who are unaware...
When patients were unaware they were taking statins there was no reported increase in musclerelated symptoms. But when patients knew they were taking a statin they were more likely to report symptoms a...
View ArticleArticles Adverse events associated with unblinded but not with blinded statin...
These analyses illustrate the socalled nocebo effect with an excess rate of musclerelated AE reports only when patients and their doctors were aware that statin therapy was being used and not when its...
View ArticleComment Statinassociated muscle symptoms beware of the nocebo effect
Patientreported statin intolerance predominantly due to statinassociated muscle symptoms SAMS is a common and difficulttomanage condition affecting millions of patients worldwide.1 Different expert...
View ArticleStatins don't cause muscle pain study
Cholesterollowering statin drugs may have been wrongly blamed for muscle pain and weakness said a study Wednesday that pointed the finger at a psychological phenomenon called the "nocebo" effect.
View ArticlePatients told about muscle pain are more likely to report it statin study finds
Patients unaware that they are taking statins do not complain of muscle pains. But the same patients once told that the drug they are taking is a statin are much more likely to report such...
View Article